To evaluate the efficacy, safety, and tolerability of multiple does strengths of MK-7240 IV infusion and subcutaneous injection compared to Placebo as assessed by the proportion of participants achieving clinical remission per Modified Mayo Score, endoscopic improvements, at designated time points. Participants aged 16 to 75 years (inclusive) with moderately …